Search results for "SART"

showing 10 items of 212 documents

Agustí Bartra i la negritud

2014

El poeta Agustí Bartra (1908-1982) va ser traductor d’alguns dels poetes neoafricans més importants del segle xx. El present treball vol incidir en les reflexions que, a propòsit d’aquestes traduccions, ens ajuden a configurar la poètica del mateix Bartra. Temes tan centrals com la funcionalitat de la poesia, el seu caràcter soteriològic, el paper del mite o del temps, són presents en Bartra com en alguns dels poetes de la negritud. Més enllà d’un interès antropològic, una efusió exòtica o revolucionària, Bartra acara la poesia neoafricana des de la seva exemplaritat, i supera, d’aquesta manera, els tractaments asimètrics, paternalistes o merament ideològics d’alguns dels qui, des d’Occiden…

lcsh:Language and LiteratureUNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASLéopold Sédar SenghorJanheinz JanhLingüísticaFilologíasAgustí Bartra; Aimé Césaire; Jean Paul Sartre; Léopold Sédar Senghor; surrealisme; primitivisme; negritud; Janheinz JanhAgustí BartrasurrealismenegritudJean Paul Sartrelcsh:Philology. Linguisticslcsh:P1-1091:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]lcsh:PprimitivismeAimé Césaire
researchProduct

Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension.

1998

The stimulation of autocrine and paracrine factors such as basic fibroblast- (bFGF) and platelet-derived (PDGF) growth factors mediates many of the growth-promoting actions of angiotensin II. The aim of this study was to evaluate the effect of chronic AT1-receptor blockade on plasma endothelin-1 (ET-1) and growth factors levels, and on left ventricular mass, in essential hypertension (EH). The study population consisted of 16 patients with mild-moderate EH, and 25 normotensive controls. In the EH patients under basal conditions, and after 3 and 6 months of chronic therapy with Losartan 50 mg/day, we measured serum levels of ET-1, bFGF and PDGF, and tumor necrosis factor (TNF). At the same t…

medicine.hormoneAdultMalemedicine.medical_specialtyAngiotensin receptorAmbulatory blood pressureHeart VentriclesEssential hypertensionLosartanEndothelinsAngiotensin Receptor AntagonistsInternal medicineBlood plasmaInternal MedicineMedicineHumansGrowth SubstancesAntihypertensive Agentsbusiness.industryEndothelinsMyocardiummedicine.diseaseAngiotensin IILosartanBlood pressureEndocrinologyChronic DiseaseHypertensionFemalebusinessmedicine.drugAmerican journal of hypertension
researchProduct

Morning and smooth 24-h ambulatory blood pressure control is not achieved in general practice: results from the SURGE observational study.

2013

BACKGROUND The aim of this large-scale, practice-based observational study [Survey with HBPM and ABPM Under Real clinical conditions in General practice to Evaluate BP control in the early morning (SURGE)] was to ascertain the degree of morning and 24-h ambulatory blood pressure (ABP) control in hypertensive patients. METHODS Hypertensive patients [with uncontrolled clinic blood pressure (BP) >140/90 mmHg at screening] from nine different countries were included. Ambulatory BP monitoring was performed over 24 h at 15-min intervals during the day and at 20-min intervals during the night. Assessments included morning (0600-1159 h) and daytime ABP control (BP < 135/85 mmHg), and 24-h ABP contr…

medicine.medical_specialtyAmbulatory blood pressuregenetic structuresPhysiologyGeneral PracticeBlood PressureLeft ventricular hypertrophyHydrochlorothiazideAmbulatory careDiabetes mellitusInternal medicineInternal MedicinemedicineAmbulatory CareHumansMorningbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseambulatory blood pressure monitoring hydrochlorothiazide telmisartanBlood pressureEndocrinologyTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients

2018

The efficacy and safety of olmesartan medoxomil (OM) vs active control (AC) monotherapy among elderly patients aged 60‐79 years (N = 4487) was evaluated by meta‐analysis (25 studies). In all patients, change from baseline to end point in blood pressure (BP) was significantly greater with OM vs AC (−19.5/−11.9 vs −16.8/−10.7 mm Hg). Greater proportions of OM‐ vs AC‐treated patients achieved BP goals. In patients with impaired renal function (estimated glomerular filtration rate <60 mL/min/1.73 m(2)), OM treatment resulted in a greater mean change from baseline in systolic BP vs AC (−21.2 vs −18.7 mm Hg, respectively) and a greater proportion of patients achieving BP goals. These parameters w…

medicine.medical_specialtyAngiotensin receptorEndocrinology Diabetes and MetabolismUrologyRenal functionBlood Pressure030204 cardiovascular system & hematologyHypertension Therapy03 medical and health sciencesImpaired renal functionAngiotensin Receptor Antagonists0302 clinical medicineDiabetes mellitusInternal MedicinemedicineHumansIn patient030212 general & internal medicineAdverse effectAgedOlmesartan Medoxomilbusiness.industryMiddle Agedmedicine.diseaseBlood pressureTreatment OutcomeHypertensionCardiology and Cardiovascular MedicineOlmesartanbusinessmedicine.drug
researchProduct

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

2020

Altres ajuts: This work was supported in part by Fundació La Marató de TV3 (201516-10, 201502-30), Societat Catalana de Cardiologia, "la Caixa" Banking Foundation. Altres ajuts: PERIS/SLT002-16-00234 Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The many peptides metabolized by NEP suggest multifaceted potential consequences of its inhibition. We sought to evaluate the short-term changes in serum endorphin (EP) values and their relation with patients' p…

medicine.medical_specialtyAngiotensin receptorEndorphins; Heart failure; Neprilysin; Sacubitril/valsartan; α-Endorphin; γ-Endorphinα‐EndorphinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]HemodynamicsPilot ProjectsHeart failure030204 cardiovascular system & hematologyγ‐EndorphinvalsartanSacubitril03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicinemedicineHumansDiseases of the circulatory (Cardiovascular) systemalpha-EndorphinOriginal Research ArticleProspective Studies030212 general & internal medicineSacubitril/valsartanγ-EndorphinAngiotensin II receptor type 1Ejection fractionbusiness.industryα-EndorphinStroke Volumegamma-Endorphinmedicine.diseaseSacubitrilValsartanRC666-701Heart failureCardiologyNeprilysinEndorphinsCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

The normal circadian pattern of blood pressure: implications for treatment

2004

Blood pressure fluctuates over 24 h following a circadian rhythm that reaches a peak in the morning shortly after awakening. The onset of many acute cardiovascular and cerebrovascular events shows a synchronous cyclical pattern, with the highest incidence of morbidity and mortality in the early morning hours. Strong, although circumstantial, evidence suggests that the early morning surge in blood pressure may contribute to the onset of acute cardiovascular episodes. Sustained blood pressure control that blunts the early morning blood pressure surge may help to reduce the incidence of these events. Antihypertensive agents are needed that provide smooth and sustained blood pressure control fo…

medicine.medical_specialtyAngiotensin receptorbusiness.industryIncidence (epidemiology)medicine.medical_treatmentChronotherapy (sleep phase)General MedicineBlood pressureInternal medicinemedicineCardiologyCircadian rhythmTelmisartanOnce dailybusinessmedicine.drugMorningInternational Journal of Clinical Practice
researchProduct

Meta-analysis of olmesartan medoxomil (OM) monotherapy in reducing blood pressure (BP) in elderly patients with hypertension (HTN)

2015

Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension (HTN) Josep Redon,y, 6 Prakash Deedwania, Kazuomi Kario, Jiguang Wang, Joris Versteden, Paul-Egbert Reimitz. Daiichi Sankyo Europe GmbH, Munich, Germany; Daiichi Sankyo Europe GmbH, Munich, Germany; Jichi University School of Medicine, Japan; Shanghai Institute of Hypertension, Shanghai, China; University of California San Francisco, San Francisco, CA, United States; University of Valencia, Madrid, Spain

medicine.medical_specialtyBlood pressurebusiness.industryInternal medicineMeta-analysisInternal MedicinemedicineIn patientCardiology and Cardiovascular MedicinebusinessOlmesartanActive controlmedicine.drugJournal of the American Society of Hypertension
researchProduct

Femoral neck’s fracture in Fahr’s Syndrome: case report

2016

Fahr's syndrome, also known as "Bilateral Striopallidodentate Calcinosis" (BSPDC) primitive, is a rare neurological disease characterized by the presence of idiopathic, bilateral, symmetrical and abnormal deposition of calcium in areas of the brain that control movements including the basal ganglia, dentate nuclei of the cerebellum, nuclei of thalamus and semi-oval center. We describe a case of a 76-year-old male patient underwent reduction and fixation of a subtrochanteric fracture with intramedullary nail. During post-operative rehabilitation therapists's patient management was difficult due to obvious extrapyramidal symptoms characterized by dysarthria, rigidity, bradykinesia, postural i…

medicine.medical_specialtyCerebellumbusiness.industryMaterials Science (miscellaneous)medicine.medical_treatmentThalamusCase ReportVentricular systemmedicine.diseaselaw.inventionFahr's syndromeIntramedullary rodDysarthriamedicine.anatomical_structurelawBasal gangliamedicineRadiologymedicine.symptombusinessReduction (orthopedic surgery)
researchProduct

Effects of the Combination of Candesartan plus Captopril in Elderly Patients with Anterior Myocardial Infarction

2000

Objective: To verify the feasibility, tolerability and efficacy of the combination of captopril (75 mg/day) and candesartan (8 mg/day) in early postinfarction phases of not thrombolysed and unreperfused anterior acute myocardial infarction (AMI) in elderly patients. Design and Patients: 71 patients (aged >65 years) hospitalised for anterior AMI were randomised in a double-blind manner into two groups: group A included 35 patients who received captopril 75 mg/day within 3 days of admission plus candesartan 4mg, as a first dose, and 8 mg/day successively; group B included 36 patients who received captopril 75 mg/day and placebo. 90 days after admission, patients underwent echocardiography to …

medicine.medical_specialtyCreatinineEjection fractionbusiness.industryCaptoprilGeneral MedicinePlacebomedicine.diseaseCandesartanchemistry.chemical_compoundBlood pressurechemistryTolerabilityInternal medicineCardiologyMedicinePharmacology (medical)Myocardial infarctionbusinessmedicine.drugClinical Drug Investigation
researchProduct

Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation.

2000

Background —Angiotensin II (Ang II) plays a critical role in the development of vascular lesions in hypertension, atherosclerosis, and several renal diseases. Because Ang II may contribute to the leukocyte recruitment associated with these pathological states, the aim of the present study was to assess the role of Ang II in leukocyte–endothelial cell interactions in vivo. Methods and Results —Intravital microscopy of the rat mesenteric postcapillary venules was used. Sixty minutes of superfusion with 1 nmol/L Ang II induced a significant increase in leukocyte rolling flux (83.8±20.7 versus 16.4±3.1 cells/min), adhesion (11.4±1.0 versus 0.8±0.5 cells/100 μm), and emigration (4.0±0.7 versus …

medicine.medical_specialtyEndotheliumPyridinesLeukocyte RollingCell CommunicationReceptor Angiotensin Type 2LosartanReceptor Angiotensin Type 1Rats Sprague-DawleyDownregulation and upregulationPhysiology (medical)Internal medicineCromolyn SodiummedicineLeukocytesAnimalsEndotheliumReceptorAngiotensin II receptor type 1Receptors Angiotensinbusiness.industryAngiotensin IIImidazolesFlow CytometryAngiotensin IIRatsUp-RegulationEndothelial stem cellP-Selectinmedicine.anatomical_structureEndocrinologyLosartanCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct